Arrowstreet Capital Limited Partnership Buys New Shares in Becton, Dickinson and Company $BDX

Arrowstreet Capital Limited Partnership purchased a new position in shares of Becton, Dickinson and Company (NYSE:BDX) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 197,345 shares of the medical instruments supplier’s stock, valued at approximately $33,993,000. Arrowstreet Capital Limited Partnership owned approximately 0.07% of Becton, Dickinson and Company at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. Saudi Central Bank acquired a new stake in shares of Becton, Dickinson and Company in the first quarter valued at about $26,000. Kelly Lawrence W & Associates Inc. CA acquired a new position in Becton, Dickinson and Company during the first quarter valued at approximately $31,000. Bell Investment Advisors Inc grew its stake in Becton, Dickinson and Company by 474.1% in the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 128 shares in the last quarter. WPG Advisers LLC bought a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $36,000. Finally, Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of Becton, Dickinson and Company by 378.9% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 182 shares of the medical instruments supplier’s stock valued at $42,000 after buying an additional 144 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

BDX opened at $193.92 on Friday. The business has a fifty day simple moving average of $188.28 and a 200 day simple moving average of $183.73. The company has a market capitalization of $55.35 billion, a PE ratio of 33.26, a price-to-earnings-growth ratio of 1.79 and a beta of 0.25. Becton, Dickinson and Company has a 1 year low of $162.29 and a 1 year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The firm had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%. Research analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be issued a $1.05 dividend. The ex-dividend date of this dividend is Monday, December 8th. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is presently 71.36%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director owned 35,816 shares in the company, valued at $6,324,389.28. This trade represents a 0.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Claire Fraser sold 917 shares of the company’s stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 1,324 shares of company stock worth $245,860. Company insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Wells Fargo & Company boosted their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Piper Sandler cut their target price on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, November 7th. Stifel Nicolaus reduced their price target on Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday, November 7th. Finally, Royal Bank Of Canada dropped their price objective on Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating on the stock in a research note on Friday, November 7th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $204.45.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.